Obesity Pillars最新文献

{"title":"What about that 2022 ICER report on anti-obesity medications?","authors":"Harold Edward Bays","doi":"10.1016/j.obpill.2022.100038","DOIUrl":"10.1016/j.obpill.2022.100038","url":null,"abstract":"","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667368122000298/pdfft?md5=4ea32404636c1aa95dc98c4f08731af4&pid=1-s2.0-S2667368122000298-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74558321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022” [Obes Pillars 2 (2022) 100018]","authors":"Harold E. Bays , Angela Fitch , Sandra Christensen , Karli Burridge , Justin Tondt","doi":"10.1016/j.obpill.2022.100035","DOIUrl":"10.1016/j.obpill.2022.100035","url":null,"abstract":"","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667368122000262/pdfft?md5=bc8249a177af015a99d286370386ef3e&pid=1-s2.0-S2667368122000262-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75500528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Weight-centric treatment of type 2 diabetes mellitus","authors":"Wissam Ghusn ,&nbsp;Maria Daniela Hurtado ,&nbsp;Andres Acosta","doi":"10.1016/j.obpill.2022.100045","DOIUrl":"10.1016/j.obpill.2022.100045","url":null,"abstract":"<div><h3>Background</h3><p>Chronic non-communicable diseases (CNCD) represent a major cause of morbidity and mortality. Type 2 diabetes mellitus (T2DM) is one of the most prevalent CNCD that is associated with a significant medical and economic burden. One of the main modifiable risk factors of T2DM is obesity. Many medications used for T2DM can lead to weight gain, worsening one of the root causes of this disease.</p></div><div><h3>Methods</h3><p>In this clinical review, we study the effect of medications for T2DM on body weight. We used MEDLINE, Google scholar, PubMed, Scopus, and Embase databases to search for relevant studies between 1 January 1950 to 20 September 2022 in English language. Here, we review the most prescribed medications for T2DM and summarize their effect on patients’ body weight. We will also present an expert opinion on a recommended weight-centric approach to treat T2DM.</p></div><div><h3>Results</h3><p>Multiple T2DM medications have been associated with weight gain. Insulin, sulfonylureas, thiazolidinediones and meglitinides may increase body weight. However, biguanides (e.g., metformin), glucagon-like peptide-1 agonists (e.g., semaglutide, liraglutide, tirzepatide), sodium-glucose cotransporter 2 inhibitors, and amylin analogs (e.g., pramlintide) are associated with significant weight loss. Dipeptidyl peptidase-4 inhibitors are considered weight neutral medications. Experts in the fields of endocrinology and obesity recommend utilizing a weight-centric approach when treating T2DM.</p></div><div><h3>Conclusion</h3><p>Considering the high prevalence and debilitating complication of T2DM, it is of utmost importance to shift from a weight gain approach (i.e., insulin, sulfonylureas) into a weight loss/neutral one (i.e., GLP-1 agonists, SGLT-2 inhibitors, metformin).</p></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667368122000365/pdfft?md5=8ecf2b56ab759c73586d4fdaea6f3137&pid=1-s2.0-S2667368122000365-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82201937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Medication-induced weight gain and advanced therapies for the child with overweight and obesity: An Obesity Medicine Association (OMA) Clinical Practice Statement 2022","authors":"Suzanne Cuda ,&nbsp;Marisa Censani ,&nbsp;Roohi Kharofa ,&nbsp;Valerie O'Hara ,&nbsp;Rushika Conroy ,&nbsp;Dominique R. Williams ,&nbsp;Jennifer Paisley ,&nbsp;Allen F. Browne ,&nbsp;Sara Karjoo ,&nbsp;Nancy T. Browne","doi":"10.1016/j.obpill.2022.100048","DOIUrl":"10.1016/j.obpill.2022.100048","url":null,"abstract":"<div><h3>Background</h3><p>This Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) details medication-induced weight gain and advanced therapies for the child with overweight or obesity.</p></div><div><h3>Methods</h3><p>The scientific information and clinical guidance in this CPS are based on scientific evidence, supported by the medical literature, and derived from the clinical perspectives of the authors.</p></div><div><h3>Results</h3><p>This OMA Clinical Practice Statement addresses medication-induced weight gain and advanced therapies for the child with overweight or obesity.</p></div><div><h3>Conclusions</h3><p>This OMA Clinical Practice Statement on medication induced-weight gain and advanced therapies for the child with overweight or obesity is an overview of current recommendations. These recommendations provide a roadmap to the improvement of the health of children and adolescents with obesity, especially those with metabolic, physiological, and psychological complications. This CPS also addresses treatment recommendations. This section is designed to help the provider with clinical decision making.</p></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667368122000390/pdfft?md5=0c2f36f0e6b5e6903678cbd8827b55a3&pid=1-s2.0-S2667368122000390-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79572841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Obesity Pillars roundtable: Excessive weight reduction with highly effective anti-obesity medications (heAOMs)","authors":"Harold Edward Bays ,&nbsp;Karli Burridge ,&nbsp;Jesse Richards ,&nbsp;Angela Fitch","doi":"10.1016/j.obpill.2022.100039","DOIUrl":"10.1016/j.obpill.2022.100039","url":null,"abstract":"<div><h3>Background</h3><p>Historically, many anti-obesity medications (AOMs) were withdrawn from development and/or the market due to safety concerns. Another challenge was that, with some exceptions, most of these AOMs had limited weight reducing efficacy. Approved AOMs often did not meet the weight reduction expectations of either clinicians, or their patients. Currently, newer approved and investigational AOMs achieve greater weight reduction than older AOMs. This has prompted an emerging new challenge of “too much weight loss” with some of these highly effective anti-obesity medications (heAOM) – something many did not think possible prior to year 2020.</p></div><div><h3>Methods</h3><p>This roundtable review includes perspectives from 3 obesity specialists with experience in the clinical use of AOMs. The intent is to provide perspectives and guidance in managing patients with obesity who experience “too much weight loss” with heAOM.</p></div><div><h3>Results</h3><p>The panelists generally agreed that before treatment with heAOMs, patients with obesity are best informed about the importance of healthful nutrition, adequate hydration, routine physical activity, behavior modification techniques, goals of treatment, and anticipated changes not only from a medical standpoint, but also from a psychosocial standpoint. Clinicians might best recognize that the definition of “excessive weight reduction” may have both objective and subjective considerations, with body composition analyses often essential to accurately assess adiposity.</p></div><div><h3>Conclusions</h3><p>The consensus of the panelists is reflected in a proposed structured and algorithmic approach to the patient with excessive weight reduction. Once properly evaluated, if the excessive weight reduction is determined most likely due to the heAOM hyper-responders, then this should prompt the clinician to educate the patient (and possibly family and friends) on the health and psychosocial aspects of weight reduction, and engage in a shared decision-making process that determines if the heAOM is best kept at the same dose, decreased in dose, temporarily held, or rare cases, best discontinued.</p></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667368122000304/pdfft?md5=764238bac02564ea5bafe7730825de13&pid=1-s2.0-S2667368122000304-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74931273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sustainable nutritional behavior change (SNBC) model: How personal nutritional decisions bring about sustainable change in nutritional behavior","authors":"Shoma Berkemeyer ,&nbsp;Johanna Wehrmann","doi":"10.1016/j.obpill.2022.100042","DOIUrl":"10.1016/j.obpill.2022.100042","url":null,"abstract":"<div><h3>Background</h3><p>The aim of this qualitative study was to identify a practice level model that could explain a sustained change in nutritional behavior.</p></div><div><h3>Methods</h3><p>The study used three data inputs from four interviewees, one merged input from a married couple, as narrative interviews. The interviews were analyzed using grounded theory.</p></div><div><h3>Results</h3><p>Coexistence of a certain suffering and a triggering episode lead to the decision to change nutritional life-style by all interviewed. Maintenance of the self-determined newly learned nutritional behavior was supported by subject-related intrinsic motivation, the ability to reflect, and a low expectation of success from the behavioral change. Environment-related factors were identified as support from life-partner and peers. Subjects reported that the sustained nutritional behavior change impacted their holistic health through subject-perceived improved life quality, increase in the number of social contacts, and a change in personal attitudes and perception. The analysis remains limited, and at best hypothesis generating, in that only three data inputs from four interviewees were used.</p></div><div><h3>Conclusion</h3><p>In this hypothesis-generating narrative interview study of four study subjects, volition, personal decision making, and long-term motivation (though not external determination) seemed to sustain a change in newly learned nutritional behavior.</p></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S266736812200033X/pdfft?md5=d6caeeb25ab225bd5589e14fa0743028&pid=1-s2.0-S266736812200033X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72948939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sleep-disordered breathing, sleep apnea, and other obesity-related sleep disorders: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022","authors":"Nicholas Pennings ,&nbsp;Leslie Golden ,&nbsp;Kanica Yashi ,&nbsp;Justin Tondt ,&nbsp;Harold Edward Bays","doi":"10.1016/j.obpill.2022.100043","DOIUrl":"10.1016/j.obpill.2022.100043","url":null,"abstract":"<div><h3>Background</h3><p>This Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) provides clinicians an overview of sleep-disordered breathing, (e.g., sleep-related hypopnea, apnea), and other obesity-related sleep disorders.</p></div><div><h3>Methods</h3><p>The scientific support for this CPS is based upon published citations, clinical perspectives of OMA authors, and peer review by the Obesity Medicine Association leadership.</p></div><div><h3>Results</h3><p>Obesity contributes to sleep-disordered breathing, with the most prevalent manifestation being obstructive sleep apnea. Obesity is also associated with other sleep disorders such as insomnia, primary snoring, and restless legs syndrome. This CPS outlines the evaluation, diagnosis, and treatment of sleep apnea and other sleep disorders, as well as the clinical implications of altered circadian system.</p></div><div><h3>Conclusions</h3><p>This Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) on “Sleep-Disordered Breathing, Sleep Apnea, and Other Obesity-Related Sleep Disorders” is one of a series of OMA CPSs designed to assist clinicians in the care of patients with the disease of obesity.</p></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667368122000341/pdfft?md5=4d4ec6f5e8080be3004412fc4cae97bd&pid=1-s2.0-S2667368122000341-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81120608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A comparison between weight loss outcomes with anti-obesity medications before and during Covid-19 pandemic at a tertiary weight management center","authors":"Alan De la Rosa ,&nbsp;Wissam Ghusn ,&nbsp;Daniel Sacoto ,&nbsp;Alejandro Campos ,&nbsp;Lizeth Cifuentes ,&nbsp;Fauzi Feris ,&nbsp;Bradley Busebee ,&nbsp;Gerardo Calderon ,&nbsp;Andres Acosta ,&nbsp;Maria D. Hurtado","doi":"10.1016/j.obpill.2022.100046","DOIUrl":"10.1016/j.obpill.2022.100046","url":null,"abstract":"<div><h3>Background</h3><p>/Objectives: Obesity is a risk factor for COVID-19 infection severity and mortality. Anti-obesity medications (AOM) are effective for weight loss. However, weight loss outcomes with AOM during the COVID-19 pandemic are yet to be described.</p></div><div><h3>Subjects</h3><p>/Methods: Between January 1, 2016, and June 30, 2021, a total of 966 patients were prescribed long-term FDA-approved AOMs at the Mayo Clinic. From these patients, 711 patients did not meet inclusion criteria. A total of 255 patients were included.</p></div><div><h3>Interventions/methods</h3><p>We performed a retrospective systematic review of electronic medical records and included patients who started a long-term FDA-approved AOM. We excluded patients with history of bariatric procedure, AOM prescription with lorcaserin, orlistat, semaglutide (approved for weight loss after the pandemic), or phentermine (short-term AOM), those taking ≥2 AOMs, &lt;3 months of prescribed AOM, and/or pregnancy. Analysis was divided by 1)preCOVID-19: those who started an AOM before COVID-19 restrictions, 2)COVID-19: those who started an AOM during first quarter of 2020 after the establishment of COVID-19 restrictions. Our primary endpoint was the total body weight loss percentage (%TBWL) at 3, 6, and 12 months after AOM initiation.</p></div><div><h3>Results</h3><p>There was a statistical difference in TBWL% between the preCOVID-19 and COVID-19 group: 5.3 ± 3.5% vs 4 ± 3.0% (95% CI -2.4 to −0.2; p = 0.02) and 9.7 ± 7.2% vs 6.2 ± 4.7% (95% CI -5.7 to −1.3; p = 0.002) at 3 and 12 months, respectively. At 6 months, the TBWL% was 7.1 for the preCOVID-19 group compared to 6.2% for the COVID-19 (95% CI -2.5 to 0.7; p = 0.25).</p></div><div><h3>Conclusion</h3><p>With the possible exception of liraglutide, this study shows that weight loss outcomes to AOMs were inferior when prescribed during the routine clinical practice throughout COVID-19 pandemic, compared to the outcomes observed prior to the COVID-19 pandemic.</p></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667368122000377/pdfft?md5=9400c01d328cb71ff06daea4ffae7f36&pid=1-s2.0-S2667368122000377-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75335774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Review of upstream social factors contributing to childhood obesity","authors":"Dominique R. Williams ,&nbsp;Amy Braddock ,&nbsp;Marcella Houser ,&nbsp;Giselle Blair,&nbsp;Nancy Browne","doi":"10.1016/j.obpill.2022.100040","DOIUrl":"10.1016/j.obpill.2022.100040","url":null,"abstract":"","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667368122000316/pdfft?md5=ec08df7e66d5897ea0478efb34e9a8dc&pid=1-s2.0-S2667368122000316-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83865462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Obesity Pillars Roundtable: Body mass index and body composition in Black and Female individuals. Race-relevant or racist? Sex-relevant or sexist?","authors":"Harold Edward Bays ,&nbsp;Sylvia Gonsahn-Bollie ,&nbsp;Courtney Younglove ,&nbsp;Sean Wharton","doi":"10.1016/j.obpill.2022.100044","DOIUrl":"10.1016/j.obpill.2022.100044","url":null,"abstract":"<div><h3>Background</h3><p>Body mass index (BMI or weight in kilograms/height in meters²) is the most common metric to diagnose overweight and obesity. However, a body composition analysis more thoroughly assesses adiposity, percent body fat, lean body mass (i.e., including skeletal muscle), and sometimes bone mineral density. BMI is not an accurate assessment of body fat in individuals with increased or decreased muscle mass; the diagnostic utility of BMI in individuals is also influenced by race and sex.</p></div><div><h3>Methods</h3><p>Previous Obesity Pillars Roundtables addressed the diagnostic limitations of BMI, the importance of android and visceral fat (especially among those with South and East Asian ancestry), and considerations of obesity among individuals who identify as Hispanic, diverse in sexual-orientation, Black, Native American, and having ancestry from the Mediterranean and Middle East regions. This roundtable examines considerations of BMI in Black and female individuals.</p></div><div><h3>Results</h3><p>The panelists agreed that body composition assessment was a more accurate measure of adiposity and muscle mass than BMI. When it came to matters of race and sex, one panelist felt: “race is a social construct and not a defining biology.” Another felt that: “BMI should be a screening tool to prompt further evaluation of adiposity that utilizes better diagnostic tools for body composition.” Regarding bias and misperceptions of resistance training in female individuals, another panelist stated: “I have spent my entire medical career taking care of women and have never seen a woman unintentionally gain ‘too much’ muscle mass and bulk up from moderate strength training.”</p></div><div><h3>Conclusions</h3><p>Conveying the importance of race and sex regarding body composition has proven challenging, with the discussion sometimes devolving into misunderstandings or misinformation that may be perceived as racist or sexist. Body composition analysis is the ultimate diagnostic equalizer in addressing the inaccuracies and biases inherent in the exclusive use of BMI.</p></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667368122000353/pdfft?md5=2c4a8bb6a4235d690bc58dfebe46f558&pid=1-s2.0-S2667368122000353-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73942388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}